Evidence map›Paper›PMID 41388144›Full record

ArticleMolecular psychiatry2026

A co-culture model of dopaminergic and glutamatergic neurons derived from patients with idiopathic schizophrenia reveals a hypodopaminergic phenotype.

Sophia-Marie Hartmann, Patricia Pizarro Garcia, Johanna Heider, Sabrina Vogel, Lisa-Sophie Wüstner, Richard Wüst, Andreas J Fallgatter, Hansjürgen Volkmer

Abstract read
In one paragraph

Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sophia-Marie HartmannMolecular Neurobiology, Department of Pharma and Biotech, NMI Natural and Medical Sciences Institute at the University of Tübingen, 72770, Reutlingen, Germany.
Patricia Pizarro GarciaMolecular Neurobiology, Department of Pharma and Biotech, NMI Natural and Medical Sciences Institute at the University of Tübingen, 72770, Reutlingen, Germany.ORCID http://orcid.org/0009-0003-9181-907X
Johanna HeiderMolecular Neurobiology, Department of Pharma and Biotech, NMI Natural and Medical Sciences Institute at the University of Tübingen, 72770, Reutlingen, Germany.ORCID http://orcid.org/0009-0006-3741-7258
Sabrina VogelMolecular Neurobiology, Department of Pharma and Biotech, NMI Natural and Medical Sciences Institute at the University of Tübingen, 72770, Reutlingen, Germany.
Lisa-Sophie WüstnerMolecular Neurobiology, Department of Pharma and Biotech, NMI Natural and Medical Sciences Institute at the University of Tübingen, 72770, Reutlingen, Germany.ORCID http://orcid.org/0000-0002-8850-2317
Richard WüstDepartment of Psychiatry, Tübingen Center for Mental Health (TüCMH), University of Tübingen, 72076, Tübingen, Germany.
Andreas J FallgatterDepartment of Psychiatry, Tübingen Center for Mental Health (TüCMH), University of Tübingen, 72076, Tübingen, Germany.
Hansjürgen VolkmerMolecular Neurobiology, Department of Pharma and Biotech, NMI Natural and Medical Sciences Institute at the University of Tübingen, 72770, Reutlingen, Germany. hansjuergenvolkmer@gmail.com.ORCID http://orcid.org/0000-0002-3867-0603

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) VO 941/10-1
6 · The paper itself

Abstract

Schizophrenia (SCZ) is a severe neurodevelopmental mental disorder characterised by a complex and multifactorial disease aetiology. Patients can suffer from both positive symptoms (e.g. hallucinations) and negative symptoms (e.g. social withdrawal) as well as cognitive impairments. The former are currently discussed to be caused by a hyperdopaminergic state in the striatum, whereas for the latter a hypodopaminergic state in the prefrontal cortex (PFC) is hypothesised. However, the underlying mechanism of hypodopaminergic signalling in the PFC, especially via the mesocortical pathway, is currently not known to any great detail. By analysing the transcriptome of iPSC-derived dopaminergic neurons from SCZ patients, we found that genes involved in dopaminergic differentiation as well as in dopamine synthesis and transport were downregulated. Furthermore, the expression of the D2 subtype of the dopamine receptor (DRD2) was also decreased, suggesting a hypodopaminergic phenotype and disinhibition of neuronal activity. Calcium imaging of a purely SCZ co-culture of human dopaminergic and glutamatergic telencephalic neurons revealed increased activity of both types of neurons, which was selectively reduced by a DRD2 agonist. Further quantification of synapse marker densities indicated a loss of glutamatergic synapses both on NGN2 and ALN neurons, whereas dopaminergic synapses were unaffected. Using mixed co-cultures comprising glutamatergic/dopaminergic neurons from healthy controls and SCZ patients, calcium imaging identified SCZ-ALN neurons as a major driver of increased activity in SCZ. Thus, the proposed model may be useful for the study of hypodopaminergic phenotypes of schizophrenia.

Indexed as

Dopaminergic NeuronsSchizophreniaAdultCell DifferentiationCoculture TechniquesDopamineFemaleGlutamic AcidHumansInduced Pluripotent Stem CellsMaleNeuronsPhenotypePrefrontal CortexReceptors, Dopamine D2SynapsesDopamineDRD2 protein, humanGlutamic AcidReceptors, Dopamine D2

Identifiers

PMID41388144
PMCPMC12999524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.